pomalidomide

Known as: 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide, 4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione, 4-Aminothalidomide 
An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
This multicenter, open-label, randomized phase 2 study assessed the efficacy and safety of pomalidomide (POM) with/without low… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND Few effective treatments exist for patients with refractory or relapsed and refractory multiple myeloma not responding… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Thalidomide and the immunomodulatory drug, lenalidomide, are therapeutically active in hematological malignancies. The… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Pomalidomide at doses of 2 or 4 mg/d has demonstrated excellent activity in patients with multiple myeloma (MM). We opened 2… (More)
  • table 2
  • table 1
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Thalidomide and lenalidomide are immunomodulatory drugs (IMiDs) that produce high remission rates in the treatment of… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Thalidomide and lenalidomide can alleviate anemia in myelofibrosis. However, their value is undermined by their… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an… (More)
  • table 1
  • table 3
  • figure 1
  • table 4
  • table 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Lenalidomide (Revlimid®; CC-5013) and pomalidomide (CC-4047) are IMiDs® proprietary drugs having immunomodulatory properties that… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?